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Background: Patients with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT) who require
dialysis are at increased risk for cardiovascular events and bone fractures. To assist in economic evaluations, this
study aimed to estimate the disutility of these events beyond the impact of CKD and SHPT.
Methods: A basic one-year health state was developed describing CKD and SHPT requiring dialysis. Further health
states added acute events (cardiovascular events, fractures, and surgical procedures) or chronic post-event effects.
Acute health states described a year including an event, and chronic health states described a year subsequent to
an event. General population participants in Canada completed time trade-off interviews from which utilities were
derived. Pairwise comparisons were made between the basic state and event, and between comparable health
states.
Results: A total of 199 participants (54.8% female; mean age = 46.3 years) completed interviews. Each health state
had ≥130 valuations. The mean (SD) utility of the basic health state was 0.60 (0.34). For acute events, mean utility
differences versus the basic state were: myocardial infarction, −0.06; unstable angina, −0.05; peripheral vascular
disease (PVD) with amputation, −0.33; PVD without amputation, −0.11; heart failure, −0.14; stroke, −0.30; hip
fracture, −0.14; arm fracture, −0.04; parathyroidectomy, +0.02; kidney transplant, +0.06. Disutilities for chronic
health states were: stable angina, −0.09; stroke, −0.27; PVD with amputation, −0.30; PVD without amputation, −0.12;
heart failure, −0.14.
Conclusions: Cardiovascular events and fractures were associated with lower utility scores, suggesting a perceived
decrease in quality of life beyond the impact of CKD and SHPT.
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Chronic kidney disease (CKD) involves a gradual and usu-
ally permanent loss of kidney function. The final stage,
end-stage renal disease (ESRD; Stage 5), is characterized by
kidney failure and the requirement for dialysis [1–3]. Most
stage 5 CKD patients have abnormal blood mineral levels
and elevated levels of parathyroid hormone (PTH), a
condition known as secondary hyperparathyroidism* Correspondence: evan.davies@evidera.com
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creativecommons.org/publicdomain/zero/1.0/(SHPT) [4–6]. Patients with CKD and SHPT typically
experience a wide range of symptoms such as bone
and joint pain, as well as psychological symptoms that
are associated with lower health-related quality of life
[7–11]. In patients with CKD, SHPT has been found
to be associated with increased resource utilization
[12], treatment costs [13], and mortality [14, 15].
CKD and SHPT are also associated with increased risk
of serious cardiovascular and bone-related complica-
tions. Cardiovascular disease is the leading cause of
death and disability in this population [16–21]. Elevatedticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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increased risk of cardiovascular events and cardiovascular-
related death in patients with CKD [18]. Sustained control
of these biomarkers is associated with increased survival
[22]. Furthermore, abnormal levels of PTH and other min-
eral metabolism indicators are associated with increased
risk of bone fractures [23, 24]. Pharmacological treatments
for PTH and mineral imbalances in CKD include vitamin
D sterols, phosphate binders, and calcimimetic agents
[2, 25–28]. When pharmacotherapy and other minimally
invasive treatment options are ineffective, surgical interven-
tions (e.g., parathyroidectomy) may be necessary [28, 29].
As new treatments are developed for patients with
CKD and SHPT, it is important to evaluate their cost-
effectiveness to demonstrate their value to clinicians and
third-party payers. Many of the cost-effectiveness ana-
lyses of CKD treatments are cost-utility models, which
incorporate the preferences of individuals for various
health states and treatment-related outcomes [5, 30–33].
In these models, treatment outcome is quantified in
terms of quality-adjusted life years (QALYs), which com-
bine duration of life and quality of life into a single
metric. The quality of life component is based on util-
ities, which are values representing the strength of pref-
erences for health states, anchored on a scale with 1
representing full health and 0 representing dead [34, 35].
Although utility values for CKD have been published
[36, 37], little is known about the utility or disutility (i.e.,
utility decrease) associated with cardiovascular events
and bone fractures in patients with CKD and SHPT.
Consequently, modelers have often had to use utility
data derived from other populations such as patients
with osteoporosis or cardiovascular disease without
CKD [30, 32, 33, 38], leading to considerable uncertainty
in the resulting cost-utility estimates. Therefore, the ob-
jective of the current study was to obtain utility values
associated with cardiovascular events and fractures in
the context of SHPT and CKD requiring dialysis. In
addition, utilities were obtained for parathyroidectomy
and kidney transplant, the two surgical procedures that
are common in this population.
Methods
Health state development
Health state descriptions were drafted based on patient
interviews, interviews with healthcare providers, and
literature review. Qualitative research was conducted
with 54 patients diagnosed with CKD and SHPT who
were receiving hemodialysis. These interviews elicited
descriptions of patients’ experience with CKD and SHPT,
including symptoms and impact. Information obtained
from the patient interviews was used when drafting
the structured interview guides for subsequent clin-
ician interviews.Telephone interviews were conducted with three
Canadian-based physicians (co-authors DM, PM, and
SS) who specialize in treatment of patients with CKD
and SHPT as well as related cardiovascular events and
fractures. Interviews were first conducted to inform
health state development, with questions focusing on
symptoms and impact of CKD and SHPT on a pa-
tient’s life, as well as the impact of dialysis treatment.
Physicians also answered questions about cardiovascu-
lar events and fractures within this patient population,
as well as differences or similarities with these events
in non-CKD patients. Health states were subsequently
drafted and then reviewed by the physicians for clarity
and accuracy.
Literature was reviewed to inform the clinician inter-
view questions and ensure that the health state descrip-
tions were consistent with published research. Literature
searches focused on CKD and SHPT [4, 8, 39]; cardio-
vascular events in the context of CKD and SHPT [40–47];
fractures in the context of CKD and SHPT [4, 5]; and
surgical interventions for patients with CKD and SHPT
[5, 39, 48].
Health states were tested in a pilot study conducted
with 19 general population participants (13 female; mean
age = 31.6 years; age range = 18 to 48) recruited through
an online advertisement. Each participant valued the
health states using both time-trade off (TTO) and stand-
ard gamble (SG) methods [49] in order to determine
which of the methods was most appropriate for the time
horizon of the task (one year). The order in which par-
ticipants completed the two tasks was randomized (11
completed SG first; eight completed TTO first). Both
TTO and SG methods yielded logical data (i.e., utilities
in a reasonable range, with logical discrimination among
health states). After completing the TTO and SG tasks
to rate the health states, participants answered a series
of qualitative questions designed to identify any issues
with the rating tasks and health states. Although the
TTO and SG methods elicited similar results, partici-
pants reported that the TTO was easier to understand
and complete. Subsequently, the TTO method with a
one-year time horizon was used in the main study. Fol-
lowing feedback from pilot study participants, minor
edits to health states were made to improve clarity and
ease of comprehension.
Final health states administered in time trade-off
interviews
The final set of health state descriptions included a
“basic health state” (health state A), which was designed
to represent a patient with CKD and SHPT on dialysis.
This health state included statements in four categories:
a description of CKD with SHPT, symptoms, impact,
and dialysis. The full text of this health state and all
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Additional 15 “event health states” (health states B–P)
included this basic health state, plus the addition of
statements describing a cardiovascular event, a fracture,
or a surgical procedure. Every health state was presented
to participants as lasting for a single hypothetical year.
Eleven of the additional health states represented car-
diovascular events (B–G and L–P). Because some of the
cardiovascular events are likely to have long-term effects
that are different from the acute experience of the event,
both acute and chronic health states were developed.
The acute health states described a year in which the
event occurred, beginning with the event itself followed
by ongoing consequences for the remainder of the year.
The chronic health states described the ongoing func-
tioning of a patient who had experienced one of these
events in a previous year. These chronic health states
can be characterized as post-event health states that
describe the chronic ongoing impact of an event that oc-
curred in the past, instead of the acute impact of the
event itself.
Six acute health states (B–G) described acute cardio-
vascular events: myocardial infarction, unstable angina,
heart failure exacerbation, peripheral vascular disease
(PVD) with amputation, PVD without amputation, and
stroke. Five chronic health states (L–P) were designed to
represent ongoing long-term impact of previous cardiovas-
cular events: stable angina (which is a possible chronic con-
dition that may follow MI or unstable angina), heart failure,
PVD with amputation, PVD without amputation, and
stroke. In each of these chronic health states, the timing of
the event was clearly explained. For example, the chronic
stroke health state (N) included the following explanation:
“Prior to this year, you experienced a stroke…The continu-
ing effects on your life include the following symptoms and
impact”.
Two health states described a fracture of the hip (H)
and a fracture of the arm (I). Consistent with clinicians’
input during the interviews, the hip fracture included
statements with more serious functional impairment
than the arm fracture. These two fracture locations were
chosen for inclusion in the health states in order to rep-
resent a broad range of the potential impact of a frac-
ture. Two surgical procedure health states describing
parathyroidectomy (J) and kidney transplant (K) were
also included to represent the potential surgical treat-
ment options for this patient group. These surgical pro-
cedures were selected based on review of the literature
and input from clinicians indicating that they are com-
mon treatment options for patients with CKD and SHPT
on dialysis [5, 39, 48, 50–52]. Parathyroidectomy was
considered important for the current set of health states
because it is directly related to the mineral imbalances
associated with SHPT.Participants
All participants were required to be (1) at least 18 years
old; (2) able to understand the assessment procedures;
(3) able and willing to give written informed consent;
and (4) residing in Canada. Inclusion criteria did not
specify particular clinical characteristics because inter-
views were intended to yield utilities that may be used in
cost-utility analyses for submission to reimbursement
authorities, most of whom prefer utilities that represent
general population values [53–56]. Participants were re-
cruited via local newspaper and online advertisements in
Toronto, Canada.
Time trade-off utility interview procedures and scoring
Utilities were derived by eliciting values for the health
state descriptions in a TTO utility interview with a one-
year time horizon conducted by a single interviewer.
The one-year time horizon was used so that the
interviews could capture the impact of relatively brief
health-related events. Each participant rated the basic
health state (A) describing CKD and SHPT with dialysis,
followed by 10 of the 15 additional health states (B–P).
The 10 event health states to be rated by each partici-
pant were determined by block randomization. To intro-
duce participants to the health state descriptions, a
ranking exercise was conducted prior to TTO utility
elicitation. Health states were presented in random order
on individual cards, and each participant ranked the
health states in order of preference.
After completing the introductory ranking task, health
state utilities were obtained using the TTO method. For
each health state, participants were offered a choice be-
tween spending a one-year period in this health state
versus spending shorter amounts of time (in one-month
increments) in the full health state. Choices varied by
one-year increments and were presented in the following
pattern: 12 months in full health, 0, 11, 1, 10, 2, 9, 3, 8,
4, 7, 5, 6. Choices were presented visually with a booklet
illustrating one choice per page. Each health state rated
as better than dead received a utility value on a scale
with the anchors of dead (0) and full health (1). The
assigned value was calculated based on the choice in
which the respondent is indifferent between y months in
the health state being evaluated and x months in full
health (followed by y – x months dead). The resulting
utility estimate (u) is calculated as u = x/y.
If participants indicated that a health state was worse
than dead, the interviewer altered the task and offered a
choice between immediate death (alternative 1) and a
one-year life span (alternative 2) beginning with varying
amounts of time in the health state being rated, followed
by full health for the remainder of the one-year time-
frame. For these health states, the current study used a
bounded scoring approach, which is commonly used to
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[49]. This scoring approach limits the utility range of
health states worse than dead to values between 0 and −1.
To compute these negative values, the current study
used the Dolan method [57] as described by Rowen &
Brazier [35]: u = −x/t, where x is the number of months
in full health, and t is the total life span of alternative
2 in the TTO choice. In the current study, t was
12 months, which is the number of months in the health
state being rated plus subsequent months in full health.
Data collection and statistical analysis procedures
Each participant attended one interview conducted in
Toronto, Canada in May 2013. Participants provided writ-
ten informed consent, completed a brief demographic and
clinical form, and then participated in a utility interview.
Participants received remuneration of C$50 for their time.
All procedures and materials were approved by an inde-
pendent Institutional Review Board (Schulman Associates
IRB; Protocol number 20130125). Statistical analyses were
completed using SAS version 9.2 (SAS Institute, Cary, NC).
Continuous variables are summarized as means and
standard deviations, and categorical variables are sum-
marized as frequencies and percentages. The difference
in utility, which may be either a disutility (i.e., utility de-
crease) or added utility (i.e., utility increase), associated
with each health-related event or treatment modality
was calculated by subtracting the utility of each event
health state (B–P) from the utility of health state A. This
utility difference quantifies the impact of each event on
preferences for one-year health states in the context of
CKD, SHPT, and dialysis. A series of independent t-tests
were conducted to compare utility scores among various
demographic subgroups (age, gender, religiosity).
Pairwise comparisons between health states, using t-
tests, were conducted to examine utility differences be-
tween health states. T-tests were considered exploratory,
and therefore no adjustments were made for multiple
comparisons. The basic health state (A) was compared
to each of the other health states that included a de-
scription of a cardiovascular, fracture, or surgical event
(B–P). T-tests were also performed to compare between
selected pairs of event health states that were conceptu-
ally comparable to each other: acute vs. chronic stroke;
arm vs. hip fracture; myocardial infarction vs. unstable
angina; and PVD with amputation vs. PVD without am-
putation. These analyses were performed to examine
whether there were differences in valuations between
specific pairs of comparable health states.
Results
Sample description
A total of 530 individuals responded to the advertise-
ments, and 264 of these were reached for screening. Ofthe 264 screened participants, 260 were eligible, 226
were scheduled for interviews, and 202 attended inter-
views. Three of the 202 participants were unable to
complete the TTO interview procedures. Thus, a total of
199 valid interviews were completed (Table 1). The sam-
ple had a mean age of 46.3 years (SD = 13.8) and was
54.8 % female. Approximately half of the sample (49.7 %)
reported no health conditions, 22.1 % reported one con-
dition, 14.6 % reported two, and 13.6 % reported greater
than two. The most common health conditions were
depression (17.1 %), arthritis (15.1 %), anxiety (13.6 %),
hypertension (13.1 %), and diabetes (9.0 %). Cardiovascu-
lar conditions were reported less frequently: heart attack
or heart disease (2.5 %) and stroke (0.5 %). No respon-
dents reported having kidney disease or other renal
conditions.
Health state utilities
Results of the introductory health state ranking task are
presented in Table 2, and TTO utilities are presented in
Fig. 1. Health state A was valued by all 199 participants
who completed the interview, while every other health
state was valued by approximately two-thirds of the
sample (n = 130 to 135). The basic health state (A) de-
scribing CKD and SHPT on dialysis without additional
clinical events had a mean utility of 0.60. Compared with
health state A, the health states describing surgical inter-
ventions had higher mean utilities of 0.61 (J, parathy-
roidectomy) and 0.65 (K, kidney transplant).
All other health states had lower mean utilities than
health state A. Utilities for health states including acute
cardiovascular events (B–G) ranged from 0.26 (E, PVD
with amputation) to 0.56 (C, unstable angina). Utilities
for chronic health states following a cardiovascular event
(L–P) ranged from 0.29 (M, PVD with amputation) to
0.52 (O, stable angina). Health state H (hip fracture) had
a utility of 0.45, while health state I (arm fracture) had a
utility of 0.56.
There were no statistically significant differences in
health state utilities between younger (n = 96) and older
(n = 103) participants categorized based on a median
split (median age = 48); male (n = 90) and female (n =
109) participants; or between participants who consid-
ered themselves religious (n = 103) and those who did
not (n = 96).
Disutilities associated with major clinical events
The disutility associated with the addition of each clin-
ical event to health state A was computed by subtracting
the utility of each event health state from the utility of
health state A (Table 3). The event health states were
identical to health state A other than the addition of the
event. Therefore, any difference in utility score between
health state A and the other health states represents the
Table 1 Demographic characteristics
Demographic characteristics Statistics
(N = 199)
Age (mean, SD) 46.3, 13.8
Gender (n, %)
Female 109 (54.8 %)
Male 90 (45.2 %)
Ethnicity* (n, %)
White 107 (53.8 %)
Black 24 (12.1 %)
Asian 52 (26.1 %)
Latin American 6 (3.0 %)
Other/Multiple 10 (5.0 %)
Marital status† (n, %)
Single 109 (54.8 %)
Married 51 (25.6 %)
Other 39 (19.6 %)
Employment status‡, (n, %)
Full-time work 65 (32.7 %)
Part-time work 57 (28.6 %)
Student 21 (10.6 %)
Retired 23 (11.6 %)
Unemployed 16 (8.0 %)
Other 17 (8.5 %)
Education Level (n, %)
Completed University Degree 125 (62.8 %)
Did not Complete University Degree 74 (37.2 %)
*Other includes participants who reported multiple categories (n = 9) and
participants who reported “other” (n = 1)
†Other includes divorced (n = 22), separated (n = 7), widowed (n = 8), and
“other” (n = 2)
‡Other includes homemaker (n = 4), disabled (n = 7), and “other” (n = 6)
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surgical events were associated with utilities higher than
the utility for health state A, with mean differences of
0.02 for parathyroidectomy (J) and 0.06 for kidney trans-
plant (K), indicating that the addition of these two
events resulted in better perceived health-related quality
of life.
All other events were associated with disutilities (i.e.,
lower utility) ranging from a mean of −0.04 to −0.33.
Mean disutilities for acute cardiovascular events (B–G)
ranged from −0.05 (C, unstable angina) to −0.33 (E,
PVD with amputation), while mean disutilities for
chronic health states following a cardiovascular event
(L–P) ranged from −0.09 (O, stable angina) to −0.30 (M,
PVD with amputation). Of the two fracture health states,
hip fracture (H) was associated with a larger mean dis-
utility (−0.14) than arm fracture (I; −0.04). Differences
between the utility of health state A and utilities of allcardiovascular and fracture health states (B–I, L–P) were
statistically significant (p < 0.0001) (Table 3).
Among selected event health states that were concep-
tually comparable to each other, the following pairwise
comparisons were statistically significant (Table 3): hip
fracture (H) and arm fracture (I) (utility difference =
0.08); PVD with and without amputation, acute (D vs. E;
utility difference = 0.19) and chronic health states (L vs.
M; utility difference = 0.16); myocardial infarction and
unstable angina (B vs. C; utility difference = 0.03).
Discussion
In the current study cardiovascular events and fractures
were associated with substantial disutility in the context
of SHPT and CKD on dialysis. It has been suggested that
differences among health state utilities of at least 0.05
can be considered clinically important [34]. The disutil-
ities of all cardiovascular events and hip fracture met or
exceeded this threshold, indicating that cardiovascular
events and major fractures have an important impact on
utility in the context of CKD and SHPT on dialysis. In
addition, the utilities of all cardiovascular and fracture
health states were significantly lower than the utility of
CKD and SHPT without these added complications. In
contrast, the two health states describing surgical inter-
ventions (J and K) were associated with higher utility
values than the basic CKD and SHPT health state (A)
due to the perceived improvements that could result
from these surgeries. While the difference associated
with parathyroidectomy was relatively small (+0.02),
kidney transplant was associated with a more substantial
utility increase (+0.06) over the basic health state. In
light of these results, it is recommended that researchers
conducting cost-utility models of treatment for CKD
and SHPT on dialysis consider incorporating the util-
ity differences associated with these important clinical
events.
A unique contribution of the current study is the iden-
tification of disutilities associated with cardiovascular
events and fractures in the context of CKD and SHPT.
Previous cost-utility analyses of treatments for CKD and
SHPT have used utilities for cardiovascular events and
fractures from outside of the context of CKD due to the
lack of utility data available for these events in this
population [30–33]. However, the literature for cardio-
vascular events is highly variable [58], making it difficult
to select the appropriate values for use in a model focus-
ing on treatment of CKD. In addition, the majority of
utilities for fractures have come from utility estimates in
osteoporosis, which may not be relevant to patients with
CKD [30–33]. Current health states were drafted based
on clinicians’ descriptions of cardiovascular and fracture
events specifically in the CKD context, and the impact
of these events on utility were rated in this context.
Table 2 Health state ranking
Health state N Mean ranking* SD Range
A. Basic HS: CKD and SHPT 199 2.0 0.6 1.0–3.0
B. Acute HS: Myocardial Infarction 130 5.7 1.9 2.0–11.0
C. Acute HS: Unstable Angina 133 4.7 1.6 2.0–9.0
D. Acute HS: PVD without amputation 135 6.1 1.8 2.0–11.0
E. Acute HS: PVD with amputation 130 9.6 1.6 3.0–11.0
F. Acute HS: Heart Failure 133 7.5 2.0 4.0–11.0
G. Acute HS: Stroke 135 9.5 1.6 2.0–11.0
H. Acute HS: Hip Fracture 130 6.3 2.0 3.0–11.0
I. Acute HS: Arm Fracture 133 3.8 1.6 2.0–9.0
J. Acute HS: Parathyroidectomy 135 2.3 1.8 1.0–11.0
K. Acute HS: Kidney Transplant 130 1.6 1.7 1.0–11.0
L. Chronic HS: PVD without amputation 133 6.6 2.0 2.0–10.0
M. Chronic HS: PVD with amputation 135 9.6 1.6 4.0–11.0
N. Chronic HS: Stroke 130 9.1 1.7 3.0–11.0
O. Chronic HS: Stable Angina 133 6.3 1.9 2.0–11.0
P. Chronic HS: Heart Failure 135 7.3 2.1 3.0–11.0
*A lower mean ranking indicates that a health state was more preferable, while a higher mean ranking indicates that a health state was less preferable
HS = health state; PVD = peripheral vascular disease; CKD = chronic kidney disease; SHPT = secondary hyperparathyroidism
Fig. 1 Time Trade-Off* Utility Scores.
*TTO utility scores are on a scale anchored with 0 representing dead and 1 representing full health. HS = health state; TTO = time trade-off;
PVD = peripheral vascular disease; CKD = chronic kidney disease; SHPT = secondary hyperparathyroidism. All 199 participants rated health state A.
Mean utilities for other health states are based on evaluations from subsets of 130 to 135 participants. The precise number of participants who
rated each health state is presented in Table 2. In this figure, acute cardiovascular health states are presented (grouped with their corresponding
chronic states) in descending order from highest utility to lowest utility. The fracture and surgical procedure health states are also ordered from
highest utility to lowest utility
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Table 3 Differences in utility scores associated with major clinical events
Health State N Mean difference score* SD T value P value
B-A. Acute HS: Myocardial Infarction 130 −0.06 0.13 −5.75 <0.0001
C-A. Acute HS: Unstable Angina 133 −0.05 0.10 −5.62 <0.0001
D-A. Acute HS: PVD without amputation 135 −0.11 0.22 −5.84 <0.0001
E-A. Acute HS: PVD with amputation 130 −0.33 0.39 −9.76 <0.0001
F-A. Acute HS: Heart Failure 133 −0.14 0.25 −6.51 <0.0001
G-A. Acute HS: Stroke 135 −0.30 0.35 −9.96 <0.0001
H-A. Acute HS: Hip Fracture 130 −0.14 0.22 −7.18 <0.0001
I-A. Acute HS: Arm Fracture 133 −0.04 0.09 −5.44 <0.0001
J-A. Acute HS: Parathyroidectomy 135 0.02 0.15 1.27 0.21
K-A. Acute HS: Kidney Transplant 130 0.06 0.25 2.73 0.0072
L-A. Chronic HS: PVD without amputation 133 −0.12 0.22 −6.25 <0.0001
M-A. Chronic HS: PVD with amputation 135 −0.30 0.32 −10.72 <0.0001
N-A. Chronic HS: Stroke 130 −0.27 0.35 −8.69 <0.0001
O-A. Chronic HS: Stable Angina 133 −0.09 0.17 −5.96 <0.0001
P-A. Chronic HS: Heart Failure 135 −0.14 0.20 −7.86 <0.0001
*This difference score was computed for each participant by subtracting the value of health state A from the value of the other health state
HS = health state; PVD = peripheral vascular disease
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priate for use in models focused on treatment for CKD
and SHPT with dialysis.
While the current cardiovascular and fracture utilities
are new in the CKD context, previous studies have re-
ported utility values for CKD itself, as well as for pa-
tients who have received kidney transplants. The utility
score of 0.60 for the health state representing CKD and
SHPT on dialysis (A) is within the range of utilities for
this type of patient obtained via a range of methods in
previous studies. For example, a review found that TTO
utilities for patients on hemodialysis across multiple
studies ranged from 0.42 to 0.73 with a mean of 0.61,
and utilities derived from the EQ-5D ranged from 0.44
to 0.62 with a mean of 0.56 [36]. Similar to results of the
current study, this review reported that kidney trans-
plant was associated with higher TTO (mean = 0.78) and
EQ-5D (mean = 0.81) utilities. Another review reported
average TTO utility means of 0.70 across studies for pa-
tients on dialysis, 0.82 for patients with kidney trans-
plant, and an EQ-5D range from 0.44 to 0.71 for
patients on dialysis [37]. The utility values for kidney
transplant were higher in both of these reviews than in
the current study, which is not unexpected since the
utilities are representing different health concepts. These
previous studies reported utilities of patients who had
previously undergone a transplant and were living in a
post-transplant state at the time of utility assessment. In
contrast, the kidney transplant health state valued in the
current study represented a year that included both the
surgical procedure and the subsequent quality of life im-
provements. While the benefits of the surgery wouldlead to a greater utility value, the procedure itself was
likely viewed as a negative event by most respondents,
which would attenuate the utility gain associated with
this health state. In sum, the previously published values
represent a post-transplant health state, while the
current utility of health state K represents a year includ-
ing the transplant as well as subsequent improvements.
The TTO interviews in the current study were con-
ducted with a one-year time horizon, and this method-
ology has yielded utility values with logical differences
among health states (differences between health states
were considered logical if the difference was in the ex-
pected direction, such as PVD with amputation having a
lower utility than PVD without amputation). In TTO
procedures, the duration of time spent in the health
state being rated (i.e., the time horizon) is an important
component of the task, and this time horizon varies
across studies. Longer time horizons, most commonly
10 years, are used more frequently, but time horizons as
short as one or two years have been shown to be useful
in several previous TTO studies [59–68]. In the current
study, the one-year time horizon was selected because a
primary goal was to quantify the utility impact of acute
events. Whereas this acute impact could be obscured if
presented as a brief event within a 10-year time horizon,
respondents clearly viewed the acute events as important
when considered within the context of a single year.
Therefore, the relatively brief time horizon seems to be
an effective approach for quantifying the utility impact
of acute events.
The time horizon does have implications for the even-
tual use of the utility scores. The health states each
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ing a path or sequence of events such as a fracture
followed by a gradual recovery. Consistent with the one-
year paths described in the health states, they were rated
in a TTO task with a one-year time horizon. Therefore,
the utilities derived from this study represent valuations
for hypothetical paths through one year of life, and can
therefore be used in a cost utility model as representing
one year. For example, the disutility of −0.06 associated
with a myocardial infarction represents utility decrement
across a single year. This disutility value would likely be
different if it were representing the impact of myocardial
infarction on a longer or shorter period of time. Conse-
quently, when using these values in a cost-utility model,
researchers need to be mindful of the timeframe, and
the current disutilities should be applied to one-year
time periods.
Modelers who intend to use the current values should
also be aware of the conceptual difference between the
acute and chronic health states. The acute health states
represent a year that includes the acute event, and the
corresponding disutility represents the utility decrement
across the full year in which the event occurs. The
chronic health states represent a post-event year, which
is a year following an event, but not including the event
itself. As with the acute health states, it is recommended
that disutilities associated with the chronic health states
be applied to a full year when used in a cost-utility
model. This one-year time horizon allows results to be
conceptualized in terms of the impact of cardiovascular
and fracture events on a QALY. For example, the differ-
ence between health states A and G represents the
QALY decrement associated with an acute stroke in the
context of CKD and SHPT. The utilities reported here
can also be used by modelers to represent trajectories of
health-related quality of life in the context of CKD with
SHPT. For instance, a patient might be in health state A
for one year (utility = 0.60), suffer a stroke in year 2
(acute health state G; utility = 0.29), and then transition
to chronic health state N representing the chronic
impact of stroke (utility = 0.32) in year 3. The total
(undiscounted) number of QALYs for the three-year
period would be 1.21, compared with 1.8 for a patient
without the stroke (i.e., 0.60*3).
The utility scores estimated in this study were derived
from members of the general population, rather than pa-
tients with the relevant medical conditions, in order to
approximate the societal viewpoint. This general popula-
tion approach is consistent with guidance provided by
health technology assessment agencies in many coun-
tries [53–56]. An advantage of a general population
sample is that, because of the widespread use of utilities
derived from general population valuations, scores de-
rived via this approach are comparable to generalpopulation valuations of other health states. There are,
of course, tradeoffs between scores obtained from the
general population and scores obtained from patients
who may have experienced some of the relevant health
states. Patients may have greater insight into the content
of health state descriptions, and therefore, patient-based
utility valuations may be grounded in a better under-
standing of the health states. In this study, a concerted
effort was made to draft health state descriptions that
accurately represented the experience of patients with
SHPT and CKD requiring dialysis, which may attenuate
some of this concern. Nonetheless, it would be useful in
future studies to compare general population and patient
scores for these health states. In the meantime, the
scores presented here may be used by modelers to esti-
mate QALYs for major clinical events in the context of
SHPT and CKD requiring dialysis.
Although this study yielded logical utilities (i.e., with
relationships among health states in the expected direc-
tions), several aspects of the study design suggest that
the results should be interpreted with appropriate cau-
tion. For example, utility assessment involving hypothet-
ical health states is limited by the accuracy and level of
detail in the health state descriptions. Therefore, utility
scores derived via these methods may differ from pa-
tients’ ratings of their own health. However, identifying
utilities associated with major clinical events directly
from patients rating their own health would be impracti-
cal for two reasons. First, it would be difficult to identify
patients and obtain utility values at the time the cardio-
vascular events or fractures occur. Second, even if a pa-
tient provides a utility at the time of the event, it may
not be feasible to isolate the impact of a cardiovascular
event or fracture on utility, separate from the impact of
CKD and SHPT. In contrast, the hypothetical health
state vignette approach used in the current study (which
could be completed by either patients or general popula-
tion respondents) is well-suited for isolating the impact
on utility of specific medical conditions, health-related
events, or treatments.
Another limitation of the current study is that the
health states specified the names of the disease and
medical events that were described. Some research has
suggested that including the disease label in a health
state can affect respondents’ valuations, while other
studies have reported situations when the label did not
affect valuations [69–71]. Although some researchers
recommend omitting the disease label from health
states, others prefer to label the medical condition as it
might minimize misunderstanding of the health state.
Furthermore, inclusion of the label more closely mirrors
the patient experience, as patients clearly know the
name of their condition. The current study included a
complex set of health states representing a diverse range
Davies et al. Health and Quality of Life Outcomes  (2015) 13:90 Page 9 of 11of medical concepts, including kidney disease, SHPT,
dialysis, cardiovascular disease, bone-related complica-
tions, two types of surgery, and acute versus chronic
effects. Therefore, each medical issue was explicitly
named to make it easier for respondents to comprehend
and differentiate between the health states. Additionally,
some of the cardiovascular states were similar to each
other (e.g., myocardial infarction and unstable angina),
and the labels were necessary to ensure that participants
did not become confused during the TTO task. How-
ever, it should be acknowledged that inclusion of the la-
bels could have influenced utility scores.
An additional limitation relates to negative utility
values. The health states in this study describe severe
medical conditions, and all health states were rated by at
least one respondent as worse than dead. With TTO
methods, health states worse than dead are rated in a
slightly different procedure than states with positive
scores, meaning that worse than dead valuations are not
measured on the same scale as states with positive
scores [49]. While this limitation is relevant to all utility
assessment, it is a more important issue when assessing
severe health states that are likely to elicit more negative
values.
Sample selection may be considered another limita-
tion. Although efforts were made to ensure that the
sample was balanced with regard to key demographic
variables such as age, gender, ethnic/racial background,
and employment status, the sample was not recruited to
be nationally representative. Furthermore, participants re-
ported relatively high rates of some clinical conditions (e.g.,
depression, arthritis, anxiety). Therefore, generalizability to
the Canadian population or the population of other coun-
tries is not known, although there is no reason to believe
that current values would be systematically different from a
nationally representative sample.
Despite limitations, the current study is a step toward
more thorough and accurate modeling of treatment for
patients with CKD and SHPT. The current utility differ-
ences associated with cardiovascular events and fractures
may be used to represent these debilitating events in cost-
utility analyses specifically focusing on patients with CKD
and SHPT on dialysis. Future research may examine
whether current values derived from health state descrip-
tions are consistent with utilities derived from actual pa-
tients who are experiencing these important clinical events.
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